Cite
HARVARD Citation
Luke, J. et al. (2021). Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. Journal for immunotherapy of cancer. 9 (2), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Luke, J. et al. (2021). Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. Journal for immunotherapy of cancer. 9 (2), p. . [Online].